https://www.biopharmawatch.com/news/CTOR/citius-oncology-lymphir-commercial-momentum BiopharmaWatch en 2026-08-05T13:17:00.000Z Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment https://www.biopharmawatch.com/news/PHG/philips-avent-share-the-care-connector-launch BiopharmaWatch en 2026-08-05T13:00:00.000Z Philips Avent introduces new automated SMS-based tool to help moms activate their village during postpartum https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-esoguard-coverage-policy BiopharmaWatch en 2026-08-05T12:46:00.000Z Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test https://www.biopharmawatch.com/news/PHGE/biomx-acquires-stake-in-motomea-electric-motor-tech BiopharmaWatch en 2026-08-05T12:45:00.000Z BiomX Acquires 10% Stake in Motomea, Inventor of Advanced Electric Motor Technologies for Drone and Autonomous Systems https://www.biopharmawatch.com/news/STE/steris-invests-600-million-north-carolina BiopharmaWatch en 2026-08-05T12:45:00.000Z STERIS To Invest $600 Million to Build a Formulated Chemistries Manufacturing and Distribution Center of Excellence in North Carolina https://www.biopharmawatch.com/news/CDIO/cardio-diagnostics-investor-call-august-2026 BiopharmaWatch en 2026-08-05T12:35:00.000Z Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026 https://www.biopharmawatch.com/news/QTI/qt-imaging-reports-q2-2026-results-conference-call BiopharmaWatch en 2026-08-05T12:30:00.000Z QT Imaging to Report Second Quarter 2026 Financial Results and Host Conference Call on August 12, 2026 https://www.biopharmawatch.com/news/GCTK/glucotrack-announces-financing-5-5-million BiopharmaWatch en 2026-08-05T12:30:00.000Z Glucotrack Announces $5.5 Million Financing https://www.biopharmawatch.com/news/BMY/schrodinger-bms-ai-drug-discovery BiopharmaWatch en 2026-08-05T12:30:00.000Z Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery https://www.biopharmawatch.com/news/FBLG/fibrobiologics-european-patent-gene-therapy-cartilage-regeneration BiopharmaWatch en 2026-08-05T12:30:00.000Z FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage https://www.biopharmawatch.com/news/ICCM/icecure-medical-h1-2026-results-report BiopharmaWatch en 2026-08-05T12:30:00.000Z IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026 https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-patent-issuance-oral-devices BiopharmaWatch en 2026-08-05T12:30:00.000Z Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology https://www.biopharmawatch.com/news/ONCO/onconetix-appoints-ralph-schiess-board-proteomedix BiopharmaWatch en 2026-08-05T12:30:00.000Z Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-share-repurchase-program-completion BiopharmaWatch en 2026-08-05T12:30:00.000Z Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-usability-study-fda-submission BiopharmaWatch en 2026-08-05T12:30:00.000Z Intelligent Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission https://www.biopharmawatch.com/news/DERM/journey-medical-q2-2026-financial-results-announcement BiopharmaWatch en 2026-08-05T12:30:00.000Z Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026 https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-phase-iib-trial-tourette-syndrome BiopharmaWatch en 2026-08-05T12:22:00.000Z SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome https://www.biopharmawatch.com/news/VNRX/volition-capture-seq-liquid-biopsy-technology BiopharmaWatch en 2026-08-05T12:17:00.000Z Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology https://www.biopharmawatch.com/news/AEMD/aethlon-medical-first-quarter-results-conference-call BiopharmaWatch en 2026-08-05T12:01:00.000Z Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026 https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-preclinical-data-eb-003 BiopharmaWatch en 2026-08-05T12:00:00.000Z Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003 https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-canaccord-genuity-conference BiopharmaWatch en 2026-08-05T12:00:00.000Z Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/TRLV/trulieve-august-2026-event-participation BiopharmaWatch en 2026-08-05T12:00:00.000Z Trulieve Announces August 2026 Event Participation https://www.biopharmawatch.com/news/DMRA/damora-therapeutics-phase-1-1b-trial-dmr-001 BiopharmaWatch en 2026-08-05T12:00:00.000Z Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis https://www.biopharmawatch.com/news/IMA/imagene-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-05T12:00:00.000Z ImageneBio Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/LFWD/lifeward-pilot-program-ottobock-rewalk-exoskeleton BiopharmaWatch en 2026-08-05T12:00:00.000Z Lifeward Launches Pilot Program with Ottobock Care to Expand National Access to ReWalk® Personal Exoskeleton https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-interim-results-2026-update BiopharmaWatch en 2026-08-05T12:00:00.000Z Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026 https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-reverse-stock-split BiopharmaWatch en 2026-08-05T12:00:00.000Z Jupiter Neurosciences, Inc. Announces Reverse Stock Split https://www.biopharmawatch.com/news/ALT/altimmune-report-q2-2026-results-business-update BiopharmaWatch en 2026-08-05T12:00:00.000Z Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 https://www.biopharmawatch.com/news/URGN/urogen-reports-zusduri-revenue-q2-2026 BiopharmaWatch en 2026-08-05T12:00:00.000Z UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights https://www.biopharmawatch.com/news/AIFF/firefly-neuroscience-tms-center-customer-growth BiopharmaWatch en 2026-08-05T11:45:00.000Z Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes https://www.biopharmawatch.com/news/IMRX/immuneering-q2-2026-financial-results-business-updates BiopharmaWatch en 2026-08-05T11:37:02.685Z Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/BVS/bioventus-q2-2026-financial-results BiopharmaWatch en 2026-08-05T11:30:00.000Z Bioventus Reports Second Quarter Financial Results https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-canaccord-genuity-conference BiopharmaWatch en 2026-08-05T11:30:00.000Z Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/MDLN/medline-reports-q2-2026-results BiopharmaWatch en 2026-08-05T11:30:00.000Z Medline Reports Second Quarter and First Six Months 2026 Results https://www.biopharmawatch.com/news/BCTX/briacell-fda-clearance-bria-pros-clinical-study-prostate-cancer BiopharmaWatch en 2026-08-05T11:30:00.000Z BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer https://www.biopharmawatch.com/news/CRVO/cervomed-fireside-chat-neflamapimod-progress BiopharmaWatch en 2026-08-05T11:30:00.000Z CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/KURA/kura-oncology-second-quarter-financial-results-2026 BiopharmaWatch en 2026-08-05T11:30:00.000Z Kura Oncology to Report Second Quarter Financial Results https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-fireside-chat-canaccord-conference BiopharmaWatch en 2026-08-05T11:27:00.000Z Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-q2-2026-financial-results BiopharmaWatch en 2026-08-05T11:05:00.000Z Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update https://www.biopharmawatch.com/news/USNA/happiness-happens-month-usana-kevin-guest BiopharmaWatch en 2026-08-05T11:03:00.000Z USANA Chairman, CEO Kevin Guest Shares 5 Ways to Make Happiness Happen at Work and Home This August https://www.biopharmawatch.com/news/ACB/aurora-cannabis-fiscal-2027-q1-results BiopharmaWatch en 2026-08-05T11:02:00.000Z Aurora Cannabis Announces Fiscal 2027 First Quarter Results https://www.biopharmawatch.com/news/FENC/fennec-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-08-05T11:01:00.000Z Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026 https://www.biopharmawatch.com/news/OFIX/orthofix-q2-2026-results-operational-progress BiopharmaWatch en 2026-08-05T11:00:00.000Z Orthofix Reports Second Quarter 2026 Results Reflecting Continued Operational Progress https://www.biopharmawatch.com/news/PODD/insulet-reports-q2-2026-results BiopharmaWatch en 2026-08-05T11:00:00.000Z Insulet Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-phase-ii-iii-harmoni-gu1-bladder-cancer BiopharmaWatch en 2026-08-05T11:00:00.000Z Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-q2-2026-financials-update BiopharmaWatch en 2026-08-05T11:00:00.000Z Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-05T11:00:00.000Z Entrada Therapeutics Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-corporate-update-q2-results BiopharmaWatch en 2026-08-05T11:00:00.000Z NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results https://www.biopharmawatch.com/news/TLX/telix-rd-day-new-york-september-2026 BiopharmaWatch en 2026-08-05T11:00:00.000Z Telix to Host R&D Day in New York City on September 22, 2026 https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-fda-rmat-designation-lx2020-pkp2-acm BiopharmaWatch en 2026-08-05T11:00:00.000Z Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy https://www.biopharmawatch.com/news/KMDA/kamada-announces-q2-2026-financial-results BiopharmaWatch en 2026-08-05T11:00:00.000Z Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026 https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-investor-conferences-2026 BiopharmaWatch en 2026-08-05T11:00:00.000Z Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-q2-2026-financial-results-call BiopharmaWatch en 2026-08-05T11:00:00.000Z Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026 https://www.biopharmawatch.com/news/INMD/inmode-q2-2026-financial-results BiopharmaWatch en 2026-08-05T11:00:00.000Z InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025 https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-05T11:00:00.000Z Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs https://www.biopharmawatch.com/news/EYPT/eyepoint-reports-q2-2026-results-and-developments BiopharmaWatch en 2026-08-05T11:00:00.000Z EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments https://www.biopharmawatch.com/news/GERN/geron-corporation-q2-2026-financial-results BiopharmaWatch en 2026-08-05T11:00:00.000Z Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/KYMR/kymera-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-05T11:00:00.000Z Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update https://www.biopharmawatch.com/news/ACIU/ac-immune-first-half-2026-update BiopharmaWatch en 2026-08-05T11:00:00.000Z AC Immune First Half 2026 Financial and Corporate Update https://www.biopharmawatch.com/news/QTTB/q32-bio-reports-q2-2026-results-corporate-update BiopharmaWatch en 2026-08-05T10:59:00.000Z Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-asn-001-acquisition BiopharmaWatch en 2026-08-05T10:50:00.000Z Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001 https://www.biopharmawatch.com/news/PLX/protalix-announces-q2-2026-financial-results BiopharmaWatch en 2026-08-05T10:50:00.000Z Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026 https://www.biopharmawatch.com/news/CMPS/compass-pathways-q2-h1-2026-results BiopharmaWatch en 2026-08-05T10:30:00.000Z Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/UTHR/united-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-05T10:30:00.000Z United Therapeutics Corporation Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/COR/cencora-reports-fiscal-2026-third-quarter-results BiopharmaWatch en 2026-08-05T10:30:00.000Z Cencora Reports Fiscal 2026 Third Quarter Results https://www.biopharmawatch.com/news/PRGO/perrigo-q2-2026-financial-results BiopharmaWatch en 2026-08-05T10:30:00.000Z Perrigo Reports Second Quarter 2026 Financial Results From Continuing Operations https://www.biopharmawatch.com/news/CVS/cvs-health-second-quarter-2026-results BiopharmaWatch en 2026-08-05T10:30:00.000Z CVS HEALTH CORPORATION REPORTS STRONG SECOND QUARTER 2026 RESULTS AND RAISES FULL-YEAR 2026 GUIDANCE https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-q2-2026-financial-results BiopharmaWatch en 2026-08-05T10:30:00.000Z Zimmer Biomet Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/RXRX/recursion-reports-q2-results-genentech-collaboration BiopharmaWatch en 2026-08-05T10:30:00.000Z Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program https://www.biopharmawatch.com/news/ELAN/elanco-animal-health-q2-2026-results BiopharmaWatch en 2026-08-05T10:27:00.000Z Elanco Animal Health Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/CVS/cvs-health-enhances-weight-management-access-glp-1 BiopharmaWatch en 2026-08-05T10:25:00.000Z CVS Health enhances its direct-to-consumer weight management offerings to improve access, affordability, care and support for GLP-1 medications https://www.biopharmawatch.com/news/NTRA/natera-signatera-japan-pmda-approval-bladder-cancer BiopharmaWatch en 2026-08-05T10:00:00.000Z Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer https://www.biopharmawatch.com/news/ONC/beone-medicines-q2-2026-results BiopharmaWatch en 2026-08-05T10:00:00.000Z BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/LIVN/livanova-q2-2026-results-revenue-guidance BiopharmaWatch en 2026-08-05T10:00:00.000Z LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance https://www.biopharmawatch.com/blog/phase-2-3-readouts-week-of-2026-08-03 BiopharmaWatch en 2026-08-05T07:15:27.469Z Upcoming Phase 3 Readouts: Key Catalysts to Watch in 2026 https://www.biopharmawatch.com/news/TWST/twist-bioscience-upsized-public-offering BiopharmaWatch en 2026-08-05T03:45:00.000Z Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock https://www.biopharmawatch.com/news/GILD/gilead-sciences-q2-2026-financial-results BiopharmaWatch en 2026-08-05T01:41:00.000Z CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-private-placement-10-million BiopharmaWatch en 2026-08-05T01:00:00.000Z Grace Therapeutics Announces $10 Million Private Placement https://www.biopharmawatch.com/news/SGHT/sight-sciences-fda-clearance-omni-ultra-surgical-system BiopharmaWatch en 2026-08-04T21:37:00.000Z Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-q2-2026-update BiopharmaWatch en 2026-08-04T21:06:00.000Z CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-q2-2026-results-update BiopharmaWatch en 2026-08-04T20:30:00.000Z DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 https://www.biopharmawatch.com/news/PACS/pacs-group-inc-reports-q2-2026-results BiopharmaWatch en 2026-08-04T20:30:00.000Z PACS Group, Inc. Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-08-04T20:30:00.000Z Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ZJYL/jin-medical-international-fy2026-financial-results BiopharmaWatch en 2026-08-04T20:30:00.000Z JIN MEDICAL INTERNATIONAL LTD. Reports First Half of Fiscal Year 2026 Financial Results https://www.biopharmawatch.com/news/ARDT/ardent-health-reports-q2-2026-results BiopharmaWatch en 2026-08-04T20:15:00.000Z Ardent Health Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/EDIT/editas-medicine-appoints-patrick-ellinor-board BiopharmaWatch en 2026-08-04T20:15:00.000Z Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D. https://www.biopharmawatch.com/news/BIO/bio-rad-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:15:00.000Z Bio-Rad Reports Second-Quarter 2026 Financial Results https://www.biopharmawatch.com/news/EHTH/ehealth-announces-q2-2026-results BiopharmaWatch en 2026-08-04T20:15:00.000Z eHealth, Inc. Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/IQV/iqvia-medera-collaboration-cardiac-gene-therapy BiopharmaWatch en 2026-08-04T20:15:00.000Z IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery https://www.biopharmawatch.com/news/ATEC/atec-reports-second-quarter-financial-results BiopharmaWatch en 2026-08-04T20:05:00.000Z ATEC Reports Second Quarter Financial Results https://www.biopharmawatch.com/news/STAA/staar-surgical-appoints-warren-foust-ceo BiopharmaWatch en 2026-08-04T20:05:00.000Z STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer https://www.biopharmawatch.com/news/HNGE/hinge-health-q2-2026-results-acquisition-cylinder-health BiopharmaWatch en 2026-08-04T20:05:00.000Z Hinge Health reports record second quarter 2026 financial results; signs definitive agreement to acquire Cylinder Health https://www.biopharmawatch.com/news/USNA/usana-health-sciences-q2-2026-results BiopharmaWatch en 2026-08-04T20:05:00.000Z USANA Health Sciences Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/JNJ/johnson-johnson-2026-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-04T20:05:00.000Z Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/HNGE/hinge-health-acquires-cylinder-health-gastrointestinal-care BiopharmaWatch en 2026-08-04T20:05:00.000Z Hinge Health to acquire Cylinder Health, expanding into gastrointestinal care https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-q2-2026-results BiopharmaWatch en 2026-08-04T20:05:00.000Z Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/XTNT/xtant-medical-participate-canaccord-growth-conference BiopharmaWatch en 2026-08-04T20:05:00.000Z Xtant Medical to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/INO/inovio-report-second-quarter-financial-results-2026 BiopharmaWatch en 2026-08-04T20:05:00.000Z INOVIO to Report Second Quarter Financial Results on August 12, 2026 https://www.biopharmawatch.com/news/TMDX/transmedics-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:05:00.000Z TransMedics Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-q2-2026-results-highlights BiopharmaWatch en 2026-08-04T20:05:00.000Z Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights https://www.biopharmawatch.com/news/KIDS/orthopediatrics-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:05:00.000Z OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:05:00.000Z PROCEPT BioRobotics Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-canaccord-growth-conference-2026 BiopharmaWatch en 2026-08-04T20:05:00.000Z Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/LENZ/lenz-therapeutics-q2-2026-financial-results-webcast BiopharmaWatch en 2026-08-04T20:05:00.000Z LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026 https://www.biopharmawatch.com/news/IRIX/iridex-q2-2026-financial-results-report BiopharmaWatch en 2026-08-04T20:05:00.000Z Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026 https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:05:00.000Z OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights https://www.biopharmawatch.com/news/LMAT/lemaitre-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:05:00.000Z LeMaitre Q2 2026 Financial Results https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:02:00.000Z Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-04T20:02:00.000Z Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/RIGL/rigel-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:01:00.000Z Rigel Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/STAA/staar-surgical-q2-2026-earnings-call BiopharmaWatch en 2026-08-04T20:01:00.000Z STAAR Surgical to Host Second Quarter 2026 Earnings Results Call and Webcast on August 12, 2026 https://www.biopharmawatch.com/news/PSNL/personalis-reports-q2-results-highlights BiopharmaWatch en 2026-08-04T20:01:00.000Z Personalis Reports Second Quarter Results and Recent Highlights https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-04T20:01:00.000Z Travere Therapeutics Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TWST/twist-bioscience-public-offering-250-million BiopharmaWatch en 2026-08-04T20:01:00.000Z Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-fiscal-2026-q3-results BiopharmaWatch en 2026-08-04T20:01:00.000Z Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results https://www.biopharmawatch.com/news/GILD/gilead-sciences-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:01:00.000Z Gilead Sciences Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AMGN/amgen-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:01:00.000Z AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS https://www.biopharmawatch.com/news/PGEN/precigen-q2-2026-financial-results-papzimeos-growth BiopharmaWatch en 2026-08-04T20:01:00.000Z Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-04T20:01:00.000Z Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-q2-2026-results-announcement BiopharmaWatch en 2026-08-04T20:01:00.000Z Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026 https://www.biopharmawatch.com/news/PCRX/pacira-biosciences-q2-2026-financial-results BiopharmaWatch en 2026-08-04T20:01:00.000Z Pacira BioSciences Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-04T20:01:00.000Z Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-acquires-fda-priority-review-voucher BiopharmaWatch en 2026-08-04T20:00:00.000Z Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-q2-2026-results-webcast BiopharmaWatch en 2026-08-04T20:00:00.000Z Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11 https://www.biopharmawatch.com/news/PNTG/pennant-acquires-river-centre-assisted-living-tucson BiopharmaWatch en 2026-08-04T20:00:00.000Z Pennant Acquires River Centre Assisted Living in Tucson, Arizona https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-brainstorm-collaboration-parkinsons-data-readout BiopharmaWatch en 2026-08-04T19:28:00.000Z Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027 https://www.biopharmawatch.com/news/NVO/novo-nordisk-q2-2026-profit-outlook BiopharmaWatch en 2026-08-04T16:37:00.000Z Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook https://www.biopharmawatch.com/news/NVO/novo-nordisk-sales-profit-outlook-2026 BiopharmaWatch en 2026-08-04T16:33:00.000Z Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026 https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-q2-2026-conference-call BiopharmaWatch en 2026-08-04T16:25:02.000Z August 12, 2026 5:00 PM EDT : The Allogene Therapeutics Second Quarter 2026 Conference Call https://www.biopharmawatch.com/news/PCVX/intellectual-fitness-suggestions-mental-health BiopharmaWatch en 2026-08-04T15:25:57.000Z Intellectual Fitness Suggestions to Show Your brain and you may Increase Better-Becoming https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-names-defendants-naked-short-selling-suit BiopharmaWatch en 2026-08-04T13:20:00.000Z Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-sil204-preclinical-findings BiopharmaWatch en 2026-08-04T13:15:00.000Z Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers https://www.biopharmawatch.com/news/IMMX/immix-biopharma-morgan-stanley-conference-2026 BiopharmaWatch en 2026-08-04T13:15:00.000Z Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/CVS/cvs-health-stevie-awards-ai-learning-academy BiopharmaWatch en 2026-08-04T13:00:00.000Z CVS Health earns two Gold and one Silver Stevie® Awards for Great Employers https://www.biopharmawatch.com/news/NVO/h1-partners-novo-nordisk-ai-clinical-development BiopharmaWatch en 2026-08-04T13:00:00.000Z H1 Partners with Novo Nordisk to Scale AI-Driven Clinical Development https://www.biopharmawatch.com/news/FEED/envue-medical-nanovibronix-manufacturing-us BiopharmaWatch en 2026-08-04T13:00:00.000Z ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-strategic-whitehawk-collaboration BiopharmaWatch en 2026-08-04T12:50:00.000Z Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation https://www.biopharmawatch.com/news/JNJ/j-j-executive-vice-president-jennifer-taubert-retire BiopharmaWatch en 2026-08-04T12:45:00.000Z Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September https://www.biopharmawatch.com/news/VERU/veru-patent-enobosarm-semaglutide-weight-loss BiopharmaWatch en 2026-08-04T12:30:00.000Z Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss https://www.biopharmawatch.com/news/EOLS/evolus-expands-partnership-symatese-estyme-canada-australia-new-zealand BiopharmaWatch en 2026-08-04T12:30:00.000Z Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand https://www.biopharmawatch.com/news/QTI/qt-imaging-advances-us-commercial-strategy-breast-ct-scanner BiopharmaWatch en 2026-08-04T12:30:00.000Z QT Imaging Advances Direct U.S. Commercial Strategy to Accelerate Adoption of its Breast Acoustic CT Scanner with Two Key Hires https://www.biopharmawatch.com/news/BAX/baxter-announces-cash-tender-offers BiopharmaWatch en 2026-08-04T12:30:00.000Z Baxter Announces Cash Tender Offers https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-canyon-1-study-crb-913-obesity BiopharmaWatch en 2026-08-04T12:30:00.000Z Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity https://www.biopharmawatch.com/news/RNXT/renovorx-highlight-tamp-platform-webinar-pancreatic-cancer BiopharmaWatch en 2026-08-04T12:30:00.000Z RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th https://www.biopharmawatch.com/news/MLSS/milestone-scientific-red-one-medical-partnership BiopharmaWatch en 2026-08-04T12:30:00.000Z Milestone Scientific Announces Strategic Federal Distribution Partnership with Red One Medical to Expand Commercial Access for the CompuFlo® Epidural System https://www.biopharmawatch.com/news/ENTX/entera-bio-phase-2-data-eb613-asbmr-2026 BiopharmaWatch en 2026-08-04T12:30:00.000Z Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-q2-2026-results-update BiopharmaWatch en 2026-08-04T12:30:00.000Z Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-04T12:30:00.000Z Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update https://www.biopharmawatch.com/news/AMIX/autonomix-medical-expands-precision-neuromodulation-platform BiopharmaWatch en 2026-08-04T12:15:00.000Z Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy https://www.biopharmawatch.com/news/XAIR/beyond-air-conference-call-financial-results-august-2026 BiopharmaWatch en 2026-08-04T12:09:57.906Z Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026 https://www.biopharmawatch.com/news/TFX/teleflex-medical-oem-launches-ingenyx BiopharmaWatch en 2026-08-04T12:09:40.695Z Teleflex Medical OEM Launches as INGENYX to Empower Tomorrow’s MedTech Innovators https://www.biopharmawatch.com/news/RANI/rani-therapeutics-appoints-michelle-gilson-board BiopharmaWatch en 2026-08-04T12:00:21.000Z Rani Therapeutics Appoints Michelle Gilson to Board of Directors https://www.biopharmawatch.com/news/ABBV/fda-acceptance-botox-masseter-muscle-prominence BiopharmaWatch en 2026-08-04T12:00:00.000Z Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence https://www.biopharmawatch.com/news/ENGN/engene-virtual-kol-event-nmibc-insights-august-2026 BiopharmaWatch en 2026-08-04T12:00:00.000Z enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026 https://www.biopharmawatch.com/news/QTRX/quanterix-report-second-quarter-2026-results BiopharmaWatch en 2026-08-04T12:00:00.000Z Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026 https://www.biopharmawatch.com/news/CVM/celsci-multikine-biomarker-strategy-study BiopharmaWatch en 2026-08-04T12:00:00.000Z CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study https://www.biopharmawatch.com/news/TWST/twist-bioscience-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-08-04T12:00:00.000Z Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NUVB/nuvation-bio-ibtrozi-pivotal-data-wclc-esmo BiopharmaWatch en 2026-08-04T12:00:00.000Z Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses https://www.biopharmawatch.com/news/ALZN/alzamend-neuro-funding-agreement-ault-lending BiopharmaWatch en 2026-08-04T12:00:00.000Z Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending https://www.biopharmawatch.com/news/LPCN/lipocine-financial-results-q2-2026 BiopharmaWatch en 2026-08-04T12:00:00.000Z Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026 https://www.biopharmawatch.com/news/IMNN/imunon-second-quarter-2026-financial-results-call BiopharmaWatch en 2026-08-04T12:00:00.000Z IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026 https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-lti-03-clinical-data-publication BiopharmaWatch en 2026-08-04T12:00:00.000Z Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications https://www.biopharmawatch.com/news/XGN/exagen-q2-2026-financial-results BiopharmaWatch en 2026-08-04T12:00:00.000Z Exagen Inc. Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-q2-2026-financial-results-highlights BiopharmaWatch en 2026-08-04T12:00:00.000Z Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-debt-equity-conversion BiopharmaWatch en 2026-08-04T12:00:00.000Z Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-04T12:00:00.000Z Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026 https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-04T12:00:00.000Z Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026 https://www.biopharmawatch.com/news/ABEO/cms-grants-ntap-status-for-zevaskyn BiopharmaWatch en 2026-08-04T11:30:00.000Z CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN® https://www.biopharmawatch.com/news/IBRX/immunitybio-record-q2-2026-revenue BiopharmaWatch en 2026-08-04T11:30:00.000Z ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-04T11:30:00.000Z Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-q2-2026-revenue-bp-205-data BiopharmaWatch en 2026-08-04T11:30:00.000Z Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-04T11:30:00.000Z Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ZVRA/zevra-therapeutics-canaccord-genuity-conference-2026 BiopharmaWatch en 2026-08-04T11:30:00.000Z Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference https://www.biopharmawatch.com/news/CAMP/camp4-therapeutics-second-closing-private-placement BiopharmaWatch en 2026-08-04T11:20:16.747Z CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement https://www.biopharmawatch.com/news/ACON/aclarion-nociscan-goodman-campbell-indiana BiopharmaWatch en 2026-08-04T11:14:39.464Z Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology https://www.biopharmawatch.com/news/SGMT/sagimet-biosciences-canaccord-genuity-conference-2026 BiopharmaWatch en 2026-08-04T11:14:25.015Z Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/NRXS/neuraxis-expands-payer-coverage-ib-stim BiopharmaWatch en 2026-08-04T11:14:02.683Z NeurAxis Expands Payer Coverage with New Policies https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-08-04T11:01:00.000Z Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/IVVD/invivyd-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-08-04T11:01:00.000Z Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-q2-2026-results-beam-302-trial BiopharmaWatch en 2026-08-04T11:00:30.000Z Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) https://www.biopharmawatch.com/news/IBIO/ibio-appoints-molly-carr-cmo-strengthens-leadership BiopharmaWatch en 2026-08-04T11:00:00.000Z iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer https://www.biopharmawatch.com/news/AHCO/adapthealth-q2-2026-results BiopharmaWatch en 2026-08-04T11:00:00.000Z AdaptHealth Corp. Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/BRKR/bruker-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-04T11:00:00.000Z Bruker Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IMDX/imdx-second-quarter-results-august-2026 BiopharmaWatch en 2026-08-04T11:00:00.000Z iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-dnth312-bifunctional-fusion-protein BiopharmaWatch en 2026-08-04T11:00:00.000Z Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases https://www.biopharmawatch.com/news/ODTX/odyssey-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-04T11:00:00.000Z Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ARVN/arvinas-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-04T11:00:00.000Z Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/TELA/tela-bio-appoints-heather-getz-ceo BiopharmaWatch en 2026-08-04T11:00:00.000Z TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-update-merger-termination BiopharmaWatch en 2026-08-04T11:00:00.000Z Lisata Therapeutics Provides Update Following Termination of Merger Agreement https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-q2-2026-update BiopharmaWatch en 2026-08-04T11:00:00.000Z Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update https://www.biopharmawatch.com/news/LH/labcorp-launches-fda-approved-pten-companion-diagnostic BiopharmaWatch en 2026-08-04T11:00:00.000Z Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-rm-718-phase-2-trial-results BiopharmaWatch en 2026-08-04T10:55:00.000Z Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity https://www.biopharmawatch.com/news/PFE/pfizer-reports-q2-results-raises-revenue-guidance BiopharmaWatch en 2026-08-04T10:45:00.000Z Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance https://www.biopharmawatch.com/news/BNTX/biontech-q2-2026-financial-results-update BiopharmaWatch en 2026-08-04T10:45:00.000Z BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update https://www.biopharmawatch.com/news/STVN/stevanato-group-revenue-growth-q2-fiscal-2026 BiopharmaWatch en 2026-08-04T10:30:00.000Z Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026 https://www.biopharmawatch.com/news/MRK/merck-second-quarter-2026-financial-results BiopharmaWatch en 2026-08-04T10:30:00.000Z Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline https://www.biopharmawatch.com/news/INFU/infusystem-financial-results-q2-2026 BiopharmaWatch en 2026-08-04T10:30:00.000Z InfuSystem Announces Financial Results for Second Quarter 2026 https://www.biopharmawatch.com/news/RVTY/revvity-financial-results-q2-2026 BiopharmaWatch en 2026-08-04T10:00:00.000Z Revvity Announces Financial Results for the Second Quarter of 2026 https://www.biopharmawatch.com/news/MD/pediatrix-medical-group-q2-results BiopharmaWatch en 2026-08-04T10:00:00.000Z Pediatrix Medical Group Reports Second Quarter Results https://www.biopharmawatch.com/news/HSIC/henry-schein-q2-2026-financial-results BiopharmaWatch en 2026-08-04T10:00:00.000Z Henry Schein Reports Strong Second Quarter 2026 Financial Results and Raises FY2026 Guidance https://www.biopharmawatch.com/news/WAT/waters-corporation-q2-2026-financial-results BiopharmaWatch en 2026-08-04T10:00:00.000Z Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-q2-2026-financial-results-update BiopharmaWatch en 2026-08-04T10:00:00.000Z IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/BDSX/biodesix-participate-canaccord-genuity-growth-conference BiopharmaWatch en 2026-08-04T10:00:00.000Z Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference https://www.biopharmawatch.com/news/CRVO/cervomed-neflamapimod-innovation-passport-dlb BiopharmaWatch en 2026-08-04T09:15:00.000Z CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB) https://www.biopharmawatch.com/news/VTGN/srx-global-acquires-stake-vistagen-therapeutics BiopharmaWatch en 2026-08-04T09:00:00.000Z SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN) https://www.biopharmawatch.com/news/PHAR/pharming-participate-canaccord-growth-conference-2026 BiopharmaWatch en 2026-08-04T06:00:00.000Z Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/PCVX/digital-platforms-enhancing-collaboration-pcvx BiopharmaWatch en 2026-08-04T05:54:21.000Z Ведущие платформы для коллективной деятельности над задачами https://www.biopharmawatch.com/news/PCVX/optimal-solutions-for-group-activities BiopharmaWatch en 2026-08-04T05:45:36.000Z Оптимальные решения для групповой деятельности над задачами https://www.biopharmawatch.com/news/PCVX/online-education-accelerated-pandemic BiopharmaWatch en 2026-08-04T05:09:18.000Z Почему онлайн-обучение превратилось свежей правилом https://www.biopharmawatch.com/news/SNY/sanofi-menquadfi-eu-approval-infants-meningococcal-disease BiopharmaWatch en 2026-08-04T05:00:00.000Z Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease https://www.biopharmawatch.com/news/NRIX/nurix-phase-3-daybreak-cll-306-trial-bexobrutideg BiopharmaWatch en 2026-08-04T05:00:00.000Z Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma https://www.biopharmawatch.com/news/PCVX/top-portable-services-for-students BiopharmaWatch en 2026-08-04T04:26:20.000Z Топовые портативные сервисы для учащихся https://www.biopharmawatch.com/news/YDES/yd-bio-peer-reviewed-publication-computational-framework BiopharmaWatch en 2026-08-04T04:17:34.000Z YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research https://www.biopharmawatch.com/news/YDES/yd-bio-tmu-collaboration-corneal-research BiopharmaWatch en 2026-08-04T04:17:32.000Z YD Bio 發表圓錐角膜研究新成果，與台北醫學大學攜手建立再生療法科學基礎 https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-08-03T22:00:00.000Z Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) https://www.biopharmawatch.com/news/APMD/apnimed-upsized-ipo-2026 BiopharmaWatch en 2026-08-03T20:35:00.000Z Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-08-03T20:30:00.000Z Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/HSTM/healthstream-announces-second-quarter-2026-results BiopharmaWatch en 2026-08-03T20:30:00.000Z HealthStream Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/TDOC/teladoc-health-appoints-mark-anquillare-board BiopharmaWatch en 2026-08-03T20:30:00.000Z Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors https://www.biopharmawatch.com/news/CV/capso-vision-launch-ai-highlights BiopharmaWatch en 2026-08-03T20:30:00.000Z CapsoVision® Announces International Launch of AI Highlights https://www.biopharmawatch.com/news/UFPT/ufp-technologies-announces-record-q2-results BiopharmaWatch en 2026-08-03T20:15:00.000Z UFP Technologies Announces Record Q2 Results https://www.biopharmawatch.com/news/TFX/teleflex-divestiture-oem-business-1-5-billion BiopharmaWatch en 2026-08-03T20:15:00.000Z Teleflex Completes Strategic Divestiture of OEM Business for $1.5 Billion https://www.biopharmawatch.com/news/HAE/vascade-mvp-xl-effectiveness-electrophysiology-procedures BiopharmaWatch en 2026-08-03T20:15:00.000Z New Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths https://www.biopharmawatch.com/news/AEON/aeon-biopharma-regains-compliance-nyse-american BiopharmaWatch en 2026-08-03T20:15:00.000Z AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-business-update-q2-2026 BiopharmaWatch en 2026-08-03T20:15:00.000Z CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SEER/seer-participate-canaccord-genuity-growth-conference BiopharmaWatch en 2026-08-03T20:15:00.000Z Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/SIBN/si-bone-reports-q2-2026-results-and-guidance BiopharmaWatch en 2026-08-03T20:09:00.000Z SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance https://www.biopharmawatch.com/news/ADUS/addus-homecare-q2-2026-financial-results BiopharmaWatch en 2026-08-03T20:05:00.000Z Addus HomeCare Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/WGS/genedx-reports-q2-2026-results BiopharmaWatch en 2026-08-03T20:05:00.000Z GeneDx Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/HIT/health-in-tech-q2-2026-financial-results-announcement BiopharmaWatch en 2026-08-03T20:05:00.000Z Health In Tech to Announce Second Quarter 2026 Financial Results on August 13, 2026 https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-08-03T20:05:00.000Z ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates https://www.biopharmawatch.com/news/SEER/seer-second-quarter-2026-financial-results BiopharmaWatch en 2026-08-03T20:05:00.000Z Seer to Report Second Quarter 2026 Financial Results on August 11, 2026 https://www.biopharmawatch.com/news/CRNX/crinetics-pharmaceuticals-q2-2026-results-update BiopharmaWatch en 2026-08-03T20:05:00.000Z Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/LGVN/longeveron-report-2026-q2-results-conference-call BiopharmaWatch en 2026-08-03T20:05:00.000Z Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026 https://www.biopharmawatch.com/news/GUTS/fractyl-health-q2-2026-financial-results-update BiopharmaWatch en 2026-08-03T20:05:00.000Z Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026 https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-q2-2026-results BiopharmaWatch en 2026-08-03T20:02:00.000Z Inspire Medical Systems, Inc. Announces Second Quarter 2026 Financial Results, Raised 2026 Guidance, and Strategic Growth Plan https://www.biopharmawatch.com/news/VRTX/vertex-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-03T20:01:00.000Z Vertex Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-q2-2026-results-updates BiopharmaWatch en 2026-08-03T20:01:00.000Z Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/KROS/keros-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-03T20:01:00.000Z Keros Therapeutics Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ARGX/argenx-extraordinary-general-meeting-september-2026 BiopharmaWatch en 2026-08-03T20:01:00.000Z argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026 https://www.biopharmawatch.com/news/PMN/promis-neurosciences-q2-2026-results-update BiopharmaWatch en 2026-08-03T20:00:00.000Z ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026 https://www.biopharmawatch.com/news/HQY/healthequity-second-quarter-earnings-release BiopharmaWatch en 2026-08-03T20:00:00.000Z HealthEquity Announces Second Quarter Earnings Release Date and Investor Conference Schedule https://www.biopharmawatch.com/news/HCSG/community-health-center-services-explained BiopharmaWatch en 2026-08-03T19:11:00.000Z In HelloNation, Healthcare Services Expert Sheila A. Berschauer Explains What a Community Health Center Can Help With https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-income-growth-q2-2026 BiopharmaWatch en 2026-08-03T18:20:00.000Z Fresenius Medical Care accelerates income growth to 23% in the second quarter of 2026 while advancing its strategic agenda https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-appoints-cassie-mclean-ceo-care-delivery BiopharmaWatch en 2026-08-03T18:20:00.000Z Fresenius Medical Care appoints Cassie McLean as new Management Board Member for Care Delivery